MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment
X.-Y. Wang National Guizhou Joint Engineering Laboratory for Cell Engineering and Biomedicine Technique, Center for Tissue Engineering and Stem Cell Research, Guizhou Province Key Laboratory of Regenerative Medicine; Department of Pharmacology, School of Basic Medicine, Guizhou Medical University, Guiyang, China. 664552160@qq.com
At present, SARS-Cov-2 is spread all over the world, becoming a serious threat to people’s health. SARS-Cov-2 has a strong infection, and the mortality rate of severe patients after infection is high, but there is no effective treatment. Mesenchymal stem cells (MSCs) have anti-inflammatory and immunomodulatory functions, which can reduce the occurrence of cytokine storm syndrome and acute respiratory distress syndrome. At the same time, MSCs can reduce the level of pulmonary fibrosis and enhance tissue injury repair. In this short report, combined with the progress of preclinical and clinical research, we comment the efficacy of MSCs in the treatment of COVID-19.
Free PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
X.-Y. Wang
MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment
Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 8
Pages: 4537-4538
DOI: 10.26355/eurrev_202004_21037